CONNECT WITH US
HealthTech

HealthTech

Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare

Fierce Biotech logo

Published on

Add as a preferred source on Google
Lilly puts up $100M, plus billions on the backend, to form 5-target deal with China's InnoCare

Eli Lilly has committed $100 million in upfront and near-term payments to InnoCare Pharma to form a five-target drug discovery pact. The deal features up to $3.25 billion in potential milestones down the line.

The partners have yet to share details of the deal’s targets or therapeutic areas, only saying that the programs address critical unmet medical needs. Beijing-based InnoCare will apply its drug discovery platform and research experience to the targets in return for upfront and near-term fees, development and commercial milestones and single-digit tiered royalties based on annual net product sales.

Partnering with InnoCare extends Lilly’s deal spree. Flush with GLP-1 cash, the drugmaker has hoovered up assets this year, striking a series of takeovers worth upward of $1 billion each while securing other R&D programs and technologies through licensing deals.

InnoCare CEO Jasmine Cui, Ph.D., discussed her own company’s approach to partnering on an earnings call last month. Reminded by an analyst that InnoCare went into 2026 targeting deals, Cui outlined business development activities the company had undertaken in the U.S. for early- and late-stage programs, such as its VAV1 degrader and TYK2 inhibitor, respectively.

But Cui said at the time that she was in no rush to partner the programs.

“We have a lot of cash, and we have our strategy for globalization, and we choose our partners very carefully,” Cui said on the August earnings call. “We are not urgent to get the cash.”

InnoCare’s VAV1 degrader and TYK2 inhibitor are part of an internal pipeline spanning hemato-oncology, autoimmune diseases and solid tumors.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.